Samuel Wickline

Samuel Wickline

Company: Altamira Therapeutics

Job title: Chief Scientific Officer


Modified Pore Forming Peptides for Self-Assembling RNA Nanoparticle Formation & Optimized Endosomal Escape 3:30 pm

Altamira’s OligoPhore and SemaPhore platforms rapidly condense any RNA into <100 nm polyplexes that are taken up by cellular macropinocytosis The peptide polyplexes avoid hepatic sequestration after systemic administration, and penetrate inflamed disease microenvironments by the “endothelial permeability and retention” (EPR) mechanism Endosomal pH-dependent polyplex disassembly releases the peptide to permeabilize the endosomal membrane for…Read more

day: Pre-Conference Day

Extrahepatic Delivery With OligoPhore & SemaPhore, Peptide-based Nanoparticles for siRNA & mRNA Therapeutics 9:30 am

Noncovalent polyplexes with any RNA that are highly stable in circulation and RNAase resistant Extrahepatic delivery and efficacy for siRNA and mRNA polyplexes have been demonstrated in myriad disease models in vivo, including cancer, atherosclerosis, arthritis, metabolic syndrome, and bowel disease Safety profiles after serial dosing in rodent models to date have been devoid of…Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.